Pomerantz LLP is investigating claims on behalf of investors of Medline Industries, Inc. regarding potential securities fraud or unlawful business practices. The investigation follows a June 2, 2026 FDA warning letter citing significant violations of Current Good Manufacturing Practice regulations, including failure to thoroughly investigate batch discrepancies. On that news, Medline’s stock fell $2.56 per share, or 7.16%, to close at $33.19 per share.
Medline Inc. Class A Common StockFDA warning letter citing significant violations of Current Good Manufacturing Practice regulations, leading to stock price decline.